Oncology Research Editorial Office

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.085502 - 21 May 2026

Abstract This article has no abstract. More >

Boqi Zhou^1,2,3, Liping Shen^2,3, Xiaojie Lu^1,2,3,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.079463 - 21 May 2026

Abstract Objectives: Gamma-aminobutyric acid type B (GABAB) receptors are involved in tumor progression, and baclofen exerts broad-spectrum antitumor effects in various cancers. Nevertheless, its specific function and underlying molecular mechanisms in glioma are still largely unclear. This study aimed to evaluate the effects of baclofen on glioma cells and elucidate the associated signaling pathways. Methods: The antitumor effects of baclofen were evaluated in glioma cell lines, and its underlying molecular mechanisms were explored using transcriptome sequencing integrated with Western blotting. The in vivo antitumor efficacy of baclofen was further verified in animal models. Results: In vitro functional assays revealed that… More >

Weixiang Song^1,#, Yanbo Zhang^2,#, Xubo Shen¹, Qin Yu¹, Yujin Liu¹, Yongchun Yu³, Rui Chen^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078665 - 21 May 2026

Abstract Objective: Osimertinib can selectively inhibit both epidermal growth factor receptor (EGFR) sensitizing and T790M gatekeeper mutations, and has shown remarkable therapeutic effects in patients with lung adenocarcinoma. However, almost all patients inevitably develop drug resistance. Herein, we sought to clarify the roles of exosomal lncRNA H19 in modulating osimertinib resistance, focusing on the PI3K-PTEN-Akt signaling axis. Methods: Functional assays, including cell viability assay, colony formation, cell apoptosis and xenograft mouse, employed in evaluate the effects of exosomal lncRNA H19 on cell growth and apoptosis. RNA quantitation and western blot were adopted to demonstrate the regulatory roles of… More >

Sebastian A. Wohlfeil^1,2,3,*, Jochen S. Utikal^1,2,3

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078650 - 21 May 2026

Abstract Over the past decade, the therapeutic paradigm of cutaneous melanoma has been transformed strongly, driven by advances in immuno-oncology and precision medicine. Building on the success of immune checkpoint blockade and targeted therapy, new treatment strategies now aim to improve efficacy, overcome resistance, and prolong the durability of responses. Clinical trials on neoadjuvant therapy supporting its clinical use are presented. Furthermore, the latest progress in combinatorial immune checkpoint inhibition such as dual anti-LAG-3 or anti-TIGIT with anti-PD-1 blockade, next-generation bispecific antibody development, mRNA-based vaccines in clinical practice, and intralesional therapies are summarized. Additionally, it outlines More >

Eun-Jeong Jeong^1,2,#, Yeon Soo Kim^2,#, Yujin Lee³, Jae-Sung Ryu⁴, Yung Hyun Choi^5,6, Eunjeong Kim^3,7,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078376 - 21 May 2026

Abstract Objective: The systematic evaluation of expansive genomic databases facilitates the discovery of clinically vital biomarkers. While Sideroflexin 3 (SFXN3) consistently displays elevated expression in head and neck squamous cell carcinoma (HNSCC), its specific pathobiological functions and prognostic value remain insufficiently characterized. This study aims to delineate the clinical and functional significance of SFXN3 in HNSCC. Methods: We interrogated SFXN3 expression patterns, patient survival outcomes, and immune cell infiltration characteristics utilizing multiple independent repositories, including the cancer genome atlas (TCGA) and gene expression omnibus (GEO). The prognostic independence of SFXN3 was verified via multivariate Cox regression. These… More > Graphic Abstract

Dat Quoc Tran¹, Mayu Takeda², Eiji Sugihara², Tetsuya Tsukamoto^2,3, Yasushi Hoshikawa⁴, Yasuyoshi Mizutani¹, Kazuya Shiogama⁵, Naoya Asai⁶, Atsuko Niimi¹, Makoto Sumitomo², Hideyuki Saya², Motoshi Suzuki^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078309 - 21 May 2026

Abstract Objectives: Genetic risk models have substantially advanced our understanding of germline pathogenic variants (GPVs) in some malignancies, whereas their clinical significance in lung cancer remains unclear. The present study aimed to better understand potential contribution of GPVs to lung cancer etiology. Methods: A targeted sequencing panel of 143 cancer-related genes was applied to analyze 26 distinct lung adenocarcinoma (LUAD) tumors from 11 patients histopathologically diagnosed with multiple primary lung cancers (MPLC). Tumor classification was performed through integrated evaluation of mutation profiles, and variants shared among tumor lesions were further validated as likely germline or somatic mutations… More >

Wei Jiang¹, You Zheng¹, Zhouhong Jing², Xiangling Yu¹, Huiying Fang^2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078278 - 21 May 2026

Abstract Background: Breast cancer treatment is often hampered by the immunosuppressive tumor microenvironment (TME). To improve therapeutic efficacy, this study developed a folic acid-chitosan (FA-CS)-modified liposomal formulation co-delivering doxorubicin (DOX) and resiquimod (R848) for combined chemotherapy and immune modulation. Methods: The FA-CS-R848/DOX@Lip liposomes were prepared by rotary evaporation and characterized for morphology, particle size, zeta potential, drug encapsulation efficiency (EE), drug loading (DL) capacity, and drug release profiles. Cellular uptake and cytotoxicity were determined to assess the biological effects of the formulation. Antitumor efficacy and biosafety were assessed in an EO771 tumor-bearing mouse model. The macrophage phenotype,… More >

Pei-Yu Kao¹, Jie-Hong Chen², Kuo-Hu Chen^1,3,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078219 - 21 May 2026

Abstract Cervical cancer remains a major global health challenge despite advances in human papillomavirus (HPV) vaccination, screening, and treatment. Persistent infection with high-risk HPV types, particularly HPV16 and HPV18, is a necessary cause of cervical cancer; however, only a small fraction of infections progress to malignancy, indicating the importance of additional cofactors. Increasing evidence identifies estrogen signaling as a critical modifier of HPV-driven carcinogenesis. Estrogen acts synergistically with HPV oncogenes E6 and E7 to promote genomic instability, immune evasion, and tumor progression, largely through effects on the tumor microenvironment (TME). This review aims to clarify and… More >

Hyungkeun Cha¹, Yong Seok Lee², Gui Young Kwon³, Boran Kim⁴, Yeonsook Moon⁵, Lucia Kim⁶, Hae-Seong Nam^1,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.077514 - 21 May 2026

Abstract Objective: Studies on the comprehensive utility of complete blood count-derived inflammatory biomarkers (CBC-IBs) as biomarkers in pembrolizumab-treated advanced non-small-cell lung cancer (NSCLC) are scarce. This study aimed to investigate the clinical relevance of a panel of CBC-IBs as potential predictive biomarkers and assess whether integrating the systemic immune-inflammation index (SII) with programmed death-ligand 1 (PD-L1) expression could overcome the limitations of PD-L1 as a standalone predictive biomarker. Methods: Our real-world preliminary study was conducted on a cohort of patients with advanced NSCLC. Patients who had undergone PD-L1 immunohistochemistry testing at the time of diagnosis, and had… More >

Kirill V. Chernov^1,#, Artemii M. Savin^1,#, Daria E. Otvodnikova¹, Oleg A. Kuchur^1,2, Sergey A. Tsymbal^1,2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.077445 - 21 May 2026

Abstract The formation of drug resistance poses the ultimate threat in modern oncology. Targeted therapy lacks versatility, while conventional therapy is famous for its side effects. However, for the new therapeutics to address the challenge of drug resistance, such compounds should combine properties of both modalities. In this review, we argue that metal-based therapeutics are paramount substances for achieving this goal. The unique physico-chemical properties and metabolism of these compounds, as well as metals themselves, allow to realize unique activities in normal and cancer cells, including precise targeting, non-apoptotic cell death, and disruption of critical signaling More > Graphic Abstract